GEOMX
Dead / Abandoned — Abandoned — failure to respond (as of 16 Jun 2022)
What this means for you
This application is over — abandoned 06 Jun 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87914539
- Mark type
- Stylized text
- Filed
- 09 May 2018
- Published for opposition
- 11 Dec 2018
- Abandoned
- 06 Jun 2022
- Attorney of record
- Alyssa Worsham
Goods and services
- Class 005 — Pharmaceuticals: diagnostic reagents and instruments for medical or veterinary use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; diagnostic reagent kits comprising primarily of diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; chemical reagents for medical use; reagents for medical or veterinary use containing antibodies and nucleic acids; diagnostic test kits for medical use comprising primarily reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical or veterinary diagnostic kits comprising medical or veterinary diagnostic reagents for use in detecting the presence of analytes in samples and identifying sample type, and equipment, namely, medical diagnostic immuno-assays for screening samples detecting the presence of analytes in samples and identifying sample type, sold as a unit with instructional manuals; diagnostic preparations in the nature of antibodies, for medical and veterinary purposes; reagents and diagnostic reagents for medical or veterinary purposes; diagnostic preparations in the nature of in situ hybridization probes, for medical and veterinary purposes; medical or veterinary diagnostic reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; multiparameter quantitative detection and analysis products and technology for diagnostics for a variety of uses in health care, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents and assays for testing of body fluids or tissue; kits consisting primarily of medical or veterinary diagnostic reagents and assays for testing of body fluids or tissue; reagents in the form of cell markers and molecule markers including antibodies and nucleic acids for medical or veterinary purposes; medical diagnostic reagents for use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents for use relating to molecular identification and digital quantification; medical diagnostic reagents containing antibodies and nucleic acids; medical diagnostic reagents for use in the fields of cancer, neurology and infectious disease; medical diagnostic reagents for immuno-histochemistry detection and in situ-hybridization detection; medical diagnostic reagents for use relating to molecular identification and digital quantification
Owner
- NanoString Technologies, Inc., Seattle, WA, US
- NanoString Technologies, Inc., Seattle, WA, US
Prosecution history
- 16 Jun 2022 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 16 Jun 2022 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 03 Dec 2021 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Dec 2021 — NON-FINAL ACTION E-MAILED
- 03 Dec 2021 — SU - NON-FINAL ACTION - WRITTEN
- 30 Aug 2021 — ASSIGNED TO EXAMINER
- 19 Aug 2021 — ASSIGNED TO EXAMINER
- 17 Aug 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Aug 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 05 Aug 2021 — USE AMENDMENT FILED
- 16 Aug 2021 — SOU EXTENSION 5 GRANTED
- 05 Aug 2021 — SOU EXTENSION 5 FILED
- 05 Aug 2021 — SOU TEAS EXTENSION RECEIVED
- 05 Aug 2021 — TEAS STATEMENT OF USE RECEIVED
- 22 Jan 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED